Prostate specific antigen has been extensively studied and represents the most common biomarker across the spectrum of prostate cancer.
Circulating tumor cells are a more recent method for monitoring patients with metastatic prostate cancer and have shown great promise in predicting outcomes. We review the prognostic capabilities of these markers to determine if circulating tumor cells should unseat prostate specific antigen as the test of choice in prostate cancer.
Written by:
Hu B, Goldkorn A. Are you the author?
Institute of Urology, Keck Medical Center of USC, University of Southern California, Los Angeles, CA, USA.
Reference: Expert Rev Anticancer Ther. 2014 Sep 9:1-4.
doi: 10.1586/14737140.2014.957190
PubMed Abstract
PMID: 25199875